Letter to the Editor

被引：37
作者：
Hastings, KL [1 ]
El-Hage, J [1 ]
Jacobs, A [1 ]
Leighton, J [1 ]
Morse, D [1 ]
Osterberg, RE [1 ]
机构：
[1] US FDA, Ctr Drug Evaluat & Res, Off New Drugs, Rockville, MD 20857 USA
来源：
TOXICOLOGY AND APPLIED PHARMACOLOGY | 2003年 / 190卷 / 01期
关键词：
D O I：
10.1016/S0041-008X(03)00150-9
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：91 / 92
页数：2
相关论文
共 8 条
  • [1] [Anonymous], 2002, IMP NEW DRUG SUBST
  • [2] Drug metabolites in safety testing
    Baillie, TA
    Cayen, MN
    Fouda, H
    Gerson, RJ
    Green, JD
    Grossman, SJ
    Klunk, LJ
    LeBlanc, B
    Perkins, DG
    Shipley, LA
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2002, 182 (03) : 188 - 196
  • [3] CALLIS AH, 1986, MOL CELLULAR MECHANI, P443
  • [4] CROY RG, 1981, CANCER RES, V41, P197
  • [5] MECHANISM OF HALOTHANE-INDUCED LIVER-INJURY - IS IT IMMUNE OR METABOLIC IDIOSYNCRASY
    FARRELL, GC
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1988, 3 (05) : 465 - 482
  • [6] Forging the links between metabolism and carcinogenesis
    Guengerich, FP
    [J]. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2001, 488 (03) : 195 - 209
  • [7] *US EPA, 1998, 8707485 US EPA OPPTS
  • [8] *US FDA, 2002, GUID MET STUD SEL RE
1